Is there a role for antigen selection in mantle cell lymphoma? Immunogenetic support from a series of 807 cases.

We examined 807 productive IGHV-IGHD-IGHJ gene rearrangements from mantle cell lymphoma (MCL) cases, by far the largest series to date. The IGHV gene repertoire was remarkably biased, with IGHV3-21, IGHV4-34, IGHV1-8, and IGHV3-23 accounting for 46.3% of the cohort. Eighty-four of 807 (10.4%) cases, mainly using the IGHV3-21 and IGHV4-34 genes, were found to bear stereotyped heavy complementarity-determining region 3 (VH CDR3) sequences and were placed in 38 clusters. Notably, the MCL stereotypes were distinct from those reported for chronic lymphocytic leukemia. Based on somatic hypermutation (SHM) status, 238/807 sequences (29.5%) carried IGHV genes with 100% germ line identity; the remainder (569/807; 70.5%) exhibited different SHM impact, ranging from minimal (in most cases) to pronounced. Shared replacement mutations across the IGHV gene were identified for certain subgroups, especially those using IGHV3-21, IGHV1-8, and IGHV3-23. Comparison with other entities, in particular CLL, revealed that several of these mutations were "MCL-biased." In conclusion, MCL is characterized by a highly restricted immunoglobulin gene repertoire with stereotyped VH CDR3s and very precise SHM targeting, strongly implying a role for antigen-driven selection of the clonogenic progenitors. Hence, an antigen-driven origin of MCL could be envisaged, at least for subsets of cases.

[1]  N. Chiorazzi,et al.  Cellular origin(s) of chronic lymphocytic leukemia: cautionary notes and additional considerations and possibilities. , 2011, Blood.

[2]  A. Wiestner,et al.  Mantle cell lymphoma: biology, pathogenesis, and the molecular basis of treatment in the genomic era. , 2011, Blood.

[3]  R. Advani,et al.  The Btk Inhibitor, PCI-32765, Induces Durable Responses with Minimal Toxicity In Patients with Relapsed/Refractory B-Cell Malignancies: Results From a Phase I Study , 2010 .

[4]  K. Stamatopoulos,et al.  The Composition of the B Cell Receptor Repertoire In 7428 Cases of Chronic Lymphocytic Leukemia: One Third Stereotyped, Two Thirds Heterogeneous - What Does This Mean? , 2010 .

[5]  F. Berger,et al.  Over 30% of Patients with Splenic Marginal Zone Lymphoma Express Distinctive Antigen Receptors Utilizing a Single Immunoglogulin Variable Gene: Implications for the Origin and Selection of the Neoplastic Cells , 2010 .

[6]  J. Tuscano,et al.  The Bispecific Anti-CD20/CD22 Antibody (Bs20x22) Has More Lymphomacidal Activity Than the Parent Antibodies Both Alone or In Combination , 2010 .

[7]  F. Rieux-Laucat,et al.  Onset of Autoimmunity In ALPS as a Consequence of Genetic Defects Accumulation , 2010 .

[8]  N. Schmitz,et al.  CNS Disease In Younger Patients ( , 2010 .

[9]  A. Berk,et al.  Dominant Negative Form of PAX5 Is Generated by Multimerization of Its DNA Binding Domain , 2010 .

[10]  David Kipling,et al.  High-throughput immunoglobulin repertoire analysis distinguishes between human IgM memory and switched memory B-cell populations. , 2010, Blood.

[11]  L. Staudt,et al.  Pathway discovery in mantle cell lymphoma by integrated analysis of high-resolution gene expression and copy number profiling. , 2010, Blood.

[12]  R. Siebert,et al.  Incidence and prognostic impact of secondary cytogenetic aberrations in a series of 145 patients with mantle cell lymphoma , 2010, Genes, chromosomes & cancer.

[13]  P. Lipsky,et al.  Identification and Characterization of a Human CD5+ Pre-Naive B Cell Population1 , 2009, The Journal of Immunology.

[14]  Xiao-Jie Yan,et al.  From bloodjournal.hematologylibrary.org at PENN STATE UNIVERSITY on February 21, 2013. For personal use only. , 2007 .

[15]  Marie-Paule Lefranc,et al.  IMGT/V-QUEST: the highly customized and integrated system for IG and TR standardized V-J and V-D-J sequence analysis , 2008, Nucleic Acids Res..

[16]  R. Rosenquist,et al.  A new perspective: molecular motifs on oxidized LDL, apoptotic cells, and bacteria are targets for chronic lymphocytic leukemia antibodies. , 2008, Blood.

[17]  A. Plebani,et al.  CpG Drives Human Transitional B Cells to Terminal Differentiation and Production of Natural Antibodies , 2008, The Journal of Immunology.

[18]  E. Thelander,et al.  Molecular genetic characterization reveals new subsets of mantle cell lymphoma , 2008, Leukemia & lymphoma.

[19]  Nikolaos Laoutaris,et al.  Stereotyped patterns of somatic hypermutation in subsets of patients with chronic lymphocytic leukemia: implications for the role of antigen selection in leukemogenesis. , 2007, Blood.

[20]  E. Campo,et al.  Genetic and molecular pathogenesis of mantle cell lymphoma: perspectives for new targeted therapeutics , 2007, Nature Reviews Cancer.

[21]  M. Neuberger,et al.  Molecular mechanisms of antibody somatic hypermutation. , 2007, Annual review of biochemistry.

[22]  J. D. Capra,et al.  A novel human B cell subpopulation representing the initial germinal center population to express AID. , 2007, Blood.

[23]  E. Schuuring,et al.  Hypermutation in mantle cell lymphoma does not indicate a clinical or biological subentity , 2006, Modern Pathology.

[24]  Nikolaos Laoutaris,et al.  Over 20% of patients with chronic lymphocytic leukemia carry stereotyped receptors: Pathogenetic implications and clinical correlations. , 2006, Blood.

[25]  Patrice Duroux,et al.  IMGT/LIGM-DB, the IMGT® comprehensive database of immunoglobulin and T cell receptor nucleotide sequences , 2005, Nucleic Acids Res..

[26]  P. Lipsky,et al.  Identification and characterization of circulating human transitional B cells. , 2005, Blood.

[27]  Ralf Küppers,et al.  Mechanisms of B-cell lymphoma pathogenesis , 2005, Nature Reviews Cancer.

[28]  Jérôme Lane,et al.  IMGT®, the international ImMunoGeneTics information system® , 2004, Nucleic Acids Res..

[29]  Steven L. Allen,et al.  Multiple Distinct Sets of Stereotyped Antigen Receptors Indicate a Role for Antigen in Promoting Chronic Lymphocytic Leukemia , 2004, The Journal of experimental medicine.

[30]  Mats Ohlin,et al.  Length of the antibody heavy chain complementarity determining region 3 as a specificity‐determining factor , 2004, Journal of molecular recognition : JMR.

[31]  M Hummel,et al.  Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: Report of the BIOMED-2 Concerted Action BMH4-CT98-3936 , 2003, Leukemia.

[32]  H. Müller-Hermelink,et al.  VH mutation status and VDJ rearrangement structure in mantle cell lymphoma: correlation with genomic aberrations, clinical characteristics, and outcome. , 2003, Blood.

[33]  D. Catovsky,et al.  A subset of t(11;14) lymphoma with mantle cell features displays mutated IgVH genes and includes patients with good prognosis, nonnodal disease. , 2003, Blood.

[34]  B. Sander,et al.  Mutated VH genes and preferential VH3-21 use define new subsets of mantle cell lymphoma. , 2003, Blood.

[35]  E. Campo,et al.  Molecular heterogeneity in MCL defined by the use of specific VH genes and the frequency of somatic mutations. , 2003, Blood.

[36]  D. Isenberg,et al.  Systematic analysis of sequences of anti-DNA antibodies—relevance to theories of origin and pathogenicity , 2002, Lupus.

[37]  R. Rosenquist,et al.  Somatic hypermutation and VH gene usage in mantle cell lymphoma , 2002, European journal of haematology.

[38]  J. Spencer,et al.  Somatic hypermutation and B-cell lymphoma. , 2001, Philosophical transactions of the Royal Society of London. Series B, Biological sciences.

[39]  M. Brüggemann,et al.  Rearrangement of the human heavy chain variable region gene V3–23 in transgenic mice generates antibodies reactive with a range of antigens on the basis of VHCDR3 and residues intrinsic to the heavy chain variable region , 2001, Clinical and experimental immunology.

[40]  J. Xu,et al.  Diversity in the CDR3 region of V(H) is sufficient for most antibody specificities. , 2000, Immunity.

[41]  D. Burton,et al.  Human autoantibody recognition of DNA. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[42]  S Henikoff,et al.  Performance evaluation of amino acid substitution matrices , 1993, Proteins.

[43]  K. Stamatopoulos,et al.  A different ontogenesis for chronic lymphocytic leukemia cases carrying stereotyped antigen receptors: molecular and computational evidence , 2010, Leukemia.

[44]  W. Hiddemann,et al.  Current treatment standards and emerging strategies in mantle cell lymphoma. , 2009, Hematology. American Society of Hematology. Education Program.

[45]  O. O’Connor Mantle cell lymphoma: identifying novel molecular targets in growth and survival pathways. , 2007, Hematology. American Society of Hematology. Education Program.

[46]  Robert Sabatier,et al.  IMGT standardized criteria for statistical analysis of immunoglobulin V‐REGION amino acid properties , 2004, Journal of molecular recognition : JMR.

[47]  Marie-Paule Lefranc,et al.  IMGT/JunctionAnalysis: the first tool for the analysis of the immunoglobulin and T cell receptor complex V-J and V-D-J JUNCTIONs , 2004, ISMB/ECCB.

[48]  V. Giudicelli,et al.  IMGT unique numbering for immunoglobulin and T cell receptor variable domains and Ig superfamily V-like domains. , 2003, Developmental and comparative immunology.

[49]  T. Hamblin,et al.  The occurrence and significance of V gene mutations in B cell-derived human malignancy. , 2001, Advances in cancer research.